PT-141 (Bremelanotide) Prescribed Online to Louisiana Residents
Sexual Wellness Treatment in Louisiana
PT-141 (Bremelanotide) is a melanocortin receptor agonist that enhances sexual desire and arousal through the central nervous system — not the vascular system. It is the first non-hormonal treatment for hypoactive sexual desire disorder approved by the FDA.
Key Benefits
- Works through the brain to enhance desire and arousal
- Effective for both men and women
- Addresses root causes of low libido rather than just physical response
- FDA-approved active ingredient (Vyleesi for women)
- Unique central mechanism distinct from PDE5 inhibitors
Who is a Good Candidate?
Men and women experiencing low sexual desire (HSDD), reduced libido, or sexual arousal difficulties who want a centrally-acting treatment that addresses desire rather than just the physical mechanics of sexual function.
Starting from $199/month
Serving Louisiana
Louisiana's unique culture deserves healthcare that's just as distinctive. From the jazz clubs of New Orleans to the oil fields of the Gulf Coast, the fishing villages of Cajun country to the business centers of Baton Rouge, OmniRx Health serves every parish. We understand that Louisiana life doesn't stop for healthcare appointments—that's why our telehealth platform fits around your schedule, whether you're working a rig rotation or running a restaurant in the French Quarter.
Our providers are licensed by the Louisiana State Board of Medical Examiners for comprehensive telehealth services statewide.
Louisiana pharmacies in New Orleans, Baton Rouge, Shreveport, and throughout Cajun country ensure prescription access with reliable delivery.
Louisiana's telehealth laws support virtual healthcare delivery with provisions for prescribing, patient privacy, and provider licensing.
Louisiana requires commercial insurers to cover telehealth, and Medicaid has expanded virtual care coverage for eligible residents.
Frequently Asked Questions
- How does PT-141 work differently from Viagra or Cialis?
- PDE5 inhibitors like sildenafil and tadalafil work by increasing blood flow to the genitals — they improve physical erectile function but do not enhance sexual desire. PT-141 activates melanocortin receptors in the brain that regulate sexual motivation and arousal, addressing the psychological and neurological dimension of sexual response that PDE5 inhibitors do not target.
- Can women use PT-141?
- Yes. PT-141 was originally developed in part to address hypoactive sexual desire disorder (HSDD) in women. Vyleesi (bremelanotide injection) is FDA-approved for premenopausal women with HSDD. It has also demonstrated benefits in men with situational erectile dysfunction related to low desire or performance anxiety.
- How and when is PT-141 administered?
- PT-141 is administered as a subcutaneous injection, typically 45 minutes to 2 hours before anticipated sexual activity to allow sufficient time for central nervous system activation. The injection site is typically the abdomen. Nausea is the most commonly reported side effect and is usually mild and temporary.
- Is telehealth legal in Louisiana?
- Yes, telehealth is legal in Louisiana. The state has comprehensive regulations supporting virtual healthcare, including provisions for prescribing medications and maintaining patient privacy.
- Can offshore workers in Louisiana use telehealth?
- Telehealth is excellent for Louisiana's offshore workers who have limited access to care during rotation. Connect with providers during breaks or when you return to shore.
- Does Louisiana Medicaid cover telehealth?
- Yes, Louisiana Medicaid covers telehealth services for eligible members. The state has expanded virtual care coverage to improve access across all parishes.